FDA Corrects Notice on BONIVA Patent Extension

Summary

The FDA is republishing a determination of the regulatory review period for BONIVA after discovering a clerical error in the effective date of the investigational new drug application (IND). The agency had previously announced the determination in June 2006, but is now correcting it due to the error.